Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - AstraZeneca PLC

21 May 2014 12:38

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION
(a) Identity of the person whose positions/dealings are being disclosed: Wellington Management Company, LLP
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

AstraZeneca PLC
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken: 20 May 2014
(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer? YES
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
Class of relevant security: Ordinary Shares (GB0009895292) and ADRs (US0463531089)
Interests Short Positions
Number % Number %
(1) Relevant securities owned and/or controlled: 64,500,768 shares 5.11 %
(2) Derivatives (other than options):
(3) Options and agreements to purchase/sell:
Total 64,500,768 shares 5.11 %
(b) Rights to subscribe for new securities (including directors’ and other executive options)
Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:
3. DEALINGS
(a) Purchases and sales
Class of relevant security Purchase/sale Number of securities Price per unit
Ordinary Shares (GB00098952922) Purchase 12,079 shares 42.8993 GBP
Ordinary Shares (GB00098952922) Sale 34,332 shares 43.0850 GBP
ADRs (US0463531089) Purchase 147,280 Depository Receipts (representing 147,280 shares on a converted basis) 71.8600 USD
(b) Derivatives transactions (other than options)
Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit
(c) Options transactions in respect of existing securities
(i) Writing, selling, purchasing or varying
Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit
(ii) Exercising
Class of relevant security Product description e.g. call option Number of securities Exercise price per unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable)
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state “none”

None
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None
(c) Attachments
Is a Supplemental Form 8 attached? NO
Date of disclosure 21 May 2014
Contact name John D. Norberg
Telephone number 617-790-7265

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel?s website at www.thetakeoverpanel.org.uk.

Copyright Business Wire 2014

Date   Source Headline
29th Feb 20161:45 pmRNSAZ REPORTS TOP-LINE RESULT OF TREMELIMUMAB TRIAL
29th Feb 20167:59 amRNSAZ enters licensing agreement with CMS for Plendil
26th Feb 201612:00 pmRNSDirector/PDMR Shareholding
25th Feb 20168:57 amRNSACALABRUTINIB ORPHAN DRUG DESIGNATION RECOMMENDED
19th Feb 20167:05 amRNSBRILIQUE APPROVED IN EU FOR HEART ATTACK PATIENTS
19th Feb 20167:00 amRNSZURAMPIC APPROVED IN EU FOR GOUT PATIENTS
17th Feb 20167:00 amRNSDurvalumab granted BTD by FDA for cancer patients
16th Feb 20168:01 amRNSNEW EXTERNAL BOARD APPOINTMENT
4th Feb 20167:00 amRNSAstraZeneca Full-Year and Q4 2015 Results
3rd Feb 20169:00 amRNSNotice of Results
3rd Feb 20167:00 amRNSTAGRISSO approved in EU for cancer patients
2nd Feb 20169:05 amRNSAZ Completes transaction with Acerta Pharma
1st Feb 20162:32 pmRNSTotal Voting Rights
28th Jan 20167:00 amRNSLynparza Granted BTD in US for Prostate Cancer
4th Jan 20162:00 pmRNSDirector/PDMR Shareholding
4th Jan 20162:00 pmRNSDirector/PDMR Shareholding
4th Jan 20161:30 pmRNSTotal Voting Rights
23rd Dec 20154:30 pmRNSResult of External Audit Tender
23rd Dec 20157:00 amRNSLESINURAD APPROVED BY US FDA FOR GOUT
18th Dec 201512:41 pmRNSTAGRISSOT (OSIMERTINIB) POSITIVE CHMP OPINION
18th Dec 201512:41 pmRNSBRILIQUE (TICAGRELOR) POSITIVE EU CHMP OPINION
18th Dec 201512:40 pmRNSCHMP ISSUES POSITIVE OPINION ON LESINURAD FOR GOUT
18th Dec 20157:00 amRNSATLANTIC TRIAL SUPPORTS CLINICAL ACTIVITY
17th Dec 20152:08 pmRNSASTRAZENECA COMPLETES ACQUISITION OF ZS PHARMA
17th Dec 20157:00 amRNSAZ INVESTS IN ACERTA PHARMA TO ENHANCE GROWTH
16th Dec 20157:12 amRNSAZ ACQUISITION OF TAKEDA'S RESPIRATORY BUSINESS
15th Dec 20153:06 pmRNSAZ COMPLETES AGREEMENT WITH PERRIGO
14th Dec 20157:56 amRNSDiscussions with Acerta Pharma BV
2nd Dec 20157:00 amRNSLate-Stage Pipeline Conference Call
1st Dec 20152:00 pmRNSBlocklisting Interim Review
1st Dec 20151:00 pmRNSTotal Voting Rights
23rd Nov 20157:00 amRNSAZ enters agreement w/ Perrigo for Entocort in US
13th Nov 20153:06 pmRNSAZD9291 Approved by the US FDA
11th Nov 20157:30 amRNSASTRAZENECA PRICES A $6 BILLION BOND ISSUE
6th Nov 20157:00 amRNSAZ acquires ZS Pharma to strengthen CVMD portfolio
5th Nov 20157:02 amRNS3rd Quarter Results
4th Nov 20159:00 amRNSNotice of Results
2nd Nov 20151:01 pmRNSTotal Voting Rights
27th Oct 20155:50 pmRNSDirector/PDMR Shareholding
26th Oct 20157:00 amRNSFDA AD COM RECOMMENDS THE APPROVAL OF LESINURAD
16th Oct 20157:00 amRNSSaxa/dapa FDC Complete Response Letter from FDA
7th Oct 20157:00 amRNSASTRAZENECA COMPLETES DIVESTMENT OF CAPRELSA
1st Oct 20154:15 pmRNSTotal Voting Rights - Replacement
1st Oct 20152:00 pmRNSDirector/PDMR Shareholding
28th Sep 20152:30 pmRNSDirector/PDMR Shareholding
28th Sep 20152:30 pmRNSDirector/PDMR Shareholding
4th Sep 20157:00 amRNSUS FDA APPROVES EXPANDED INDICATION FOR BRILINTA
1st Sep 201511:30 amRNSTotal Voting Rights
1st Sep 20157:04 amRNSAstraZeneca and Valeant to partner on brodalumab
28th Aug 20154:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.